These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 26930330)

  • 21. Experience with erlotinib in the treatment of non-small cell lung cancer.
    Landi L; Cappuzzo F
    Ther Adv Respir Dis; 2015 Aug; 9(4):146-63. PubMed ID: 26063687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detecting Laryngopharyngeal Reflux by Immunohistochemistry of Pepsin in the Biopsies of Vocal Fold Leukoplakia.
    Gong X; Wang XY; Yang L; Sun MJ; Du J; Zhang W
    J Voice; 2018 May; 32(3):352-355. PubMed ID: 28756936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic Yield of Office-Based Laryngeal Biopsy in Patients With Leukoplakia; A Case Study With Review of the Literature.
    Hamdan AL; Ghanem A; Natout TE; Khalifee E
    J Voice; 2023 Mar; 37(2):282-286. PubMed ID: 33516647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib as first line treatment in a NSCLC patient with choroidal metastasis and with EGFR exon 19 deletion.
    Kocoglu H; Karaca M; Turkay R; Tural D
    J BUON; 2016; 21(3):754-5. PubMed ID: 27569104
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatic metastasis is a poor predictive marker for erlotinib in lung adenocarcinoma.
    He Y; Wang Y; Zhang S; Ren S; Li J; Zhou C
    Med Hypotheses; 2016 Sep; 94():20-2. PubMed ID: 27515192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological parameters associated with histological background and recurrence after surgical intervention of vocal cord leukoplakia.
    Cui W; Xu W; Yang Q; Hu R
    Medicine (Baltimore); 2017 Jun; 96(22):e7033. PubMed ID: 28562558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib.
    Xie S; Li Y; Li X; Wang L; Yang N; Wang Y; Wei H
    Oncotarget; 2015 Apr; 6(11):9206-19. PubMed ID: 25826078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and pathological characteristics of vocal fold leukoplakia and influential factors of recurrence and malignancy].
    Cui WX; Xu W; Yang QW; Cheng LY
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 30(24):1926-1931. PubMed ID: 29798266
    [No Abstract]   [Full Text] [Related]  

  • 31. [Observation of clinicopathological characteristics of vocal fold leukoplakia and laryngopharyngeal reflux].
    Zhu H; Xu W; Li Y; Cheng L
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 May; 49(5):368-73. PubMed ID: 25017219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
    Garassino MC; Martelli O; Broggini M; Farina G; Veronese S; Rulli E; Bianchi F; Bettini A; Longo F; Moscetti L; Tomirotti M; Marabese M; Ganzinelli M; Lauricella C; Labianca R; Floriani I; Giaccone G; Torri V; Scanni A; Marsoni S;
    Lancet Oncol; 2013 Sep; 14(10):981-8. PubMed ID: 23883922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiolytic laser stripping versus CO2 laser microflap excision for vocal fold leukoplakia: Long-term disease control and voice outcomes.
    Lim JY; Park YM; Kang M; Lee SJ; Baek K; Na J; Choi HS
    PLoS One; 2018; 13(12):e0209691. PubMed ID: 30596718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
    Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation.
    Hirano S; Naka G; Takeda Y; Iikura M; Hayama N; Yanagisawa A; Amano H; Nakamura M; Nakamura S; Tabeta H; Sugiyama H
    Chin Clin Oncol; 2016 Dec; 5(6):77. PubMed ID: 28061541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
    Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.
    Clark GM; Zborowski DM; Culbertson JL; Whitehead M; Savoie M; Seymour L; Shepherd FA
    J Thorac Oncol; 2006 Oct; 1(8):837-46. PubMed ID: 17409968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.